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Abstract
Background: Non-allergic rhinopathy (NAR), formerly known as vasomotor rhinitis, is a non-allergic and non-
infectious chronic disease that is accompanied by nasal hyperemia, rhinorrhea, and no increase in the number of
eosinophils. Although the medications for NAR, including intranasal corticosteroids and intranasal antihistamine,
have been used in clinical practice, given the relative paucity of effective therapy with available medications,
alternative non-pharmacologic treatments could play an important role in treating NAR. Acupuncture treatment is
representative potential alternative therapy for the treatment of various diseases, including rhinitis. Therefore, the
objective of this study was to evaluate the efficacy of pricking blood at Neiyingxiang (ExHN 9) relative to
acupuncture treatment at Waiyingxiang (LI 20) in patients with NAR.
Methods/Design: A randomized, parallel-group, controlled, assessor single-blinded, trial will be conducted. Fifty
participants with NAR will be randomized into one of two groups: either the control group with acpuncture
treatment at LI 20 or the experimental group with pricking blood at ExHN 9. After randomization, a total of three
sessions of treatment will be performed once a week in both groups. The total nasal symptom score (TNSS) and
the Mini-Rhinoconjunctivitis Quality-of-Life Questionnaire (MiniRQLQ) at baseline and the end of the trial will be
used to evaluate the efficacy of each treatment.
Discussion: This study will be the first randomized trial to evaluate the efficacy of pricking blood for the treatment
of NAR. The results of this study will help establish an alternative approach for treating patients with NAR that do
not respond to Western medication.
Trial registration: The trial was registered with the Clinical Research Information Service (CRiS), Republic of Korea:
KCT0000195.
Background
Non-allergic rhinopathy (NAR), formerly known as vaso-
motor rhinitis, is a chronic non-infectious and non-allergic
condition that displays the following symptoms: predomi-
nantly nasal congestion and rhinorrhea, which may be per-
ennial, persistent, intermittent, or seasonal [1,2]. Unlike
allergic rhinitis (AR), which is elicited by specific antigens,
NAR is not relevant to allergen exposure and may be trig-
gered by cold air, changes in climate or sexual hormone
levels, strong smells, environmental tobacco smoke,
pollutants, chemicals, exercise, or alcohol ingestion [1]. The
exact prevalence of NAR has not been as well established
as allergic rhinitis and one study suggested a relative preva-
lence rate of 76% for AR and 24% for non-allergic rhinitis,
which corresponds to an approximate ratio of 3:1 [1,3].
The medications used for treating NAR have been stu-
died less widely than those for AR [1]. The management
of NAR consists of avoiding trigger factors in combina-
tion with medication, including intranasal corticosteroids,
intranasal antihistamines, anti-cholinergics, decongestants,
and nasal saline [1-5]. Even though patients with NAR
are administered these medications, some patients do not
adequately respond to them. For these patients, other
agents can be considered such as capsaicin, botulinum
toxin A, antileukotrienes, silver nitrate, or acupuncture
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peutic agents with available medications, alternative non-
pharmacologic therapies could play an important role in
treating NAR.
Acupuncture has been used widely in East Asia and Eur-
ope for the treatment of various kinds of diseases, includ-
ing rhinitis. In a systematic review that evaluated the
clinical effectiveness of acupuncture for treating or pre-
venting allergic rhinitis in 2009, acupuncture was found to
be ineffective in the treatment of seasonal AR; however,
acupuncture was shown to be effective for the treatment
of perennial AR [6]. Recently, acupuncture treatment was
s h o w nt ob ee f f e c t i v ei ni m p r o v i n gt h es y m p t o m so f
patients with persistent allergic rhinitis complicated by
rhinosinusitis and asthma [7]. However, the majority of
studies on acupuncture treatment have only examined AR
and there were seldom randomized controlled trials.
There has only been one randomized controlled pilot trial
that showed a significant change in the nasal sickness
score of patients with vasomotor rhinitis [8].
In Oriental medicine, Waiyingxiang (LI 20) is gener-
ally used in clinical practice to treat local diseases of the
nose including rhinitis, sinusitis, and olfactory disorders
[7-12]. Neiyingxiang (ExHN 9) is located at the junction
between the mucosa of the alar cartilage of the nose
and the nasal concha in the nostril and is commonly
used for olfactory disorders, chronic rhinitis, sequela of
Bell’s palsy, and headache [13-15].
Therefore, we will conduct a randomized controlled
pilot trial to assess the efficacy of pricking blood at
ExHN 9 relative to acupuncture treatment at the LI 20
in patients with NAR.
Method/Design
Objective
The current randomized, assessor single-blinded, parallel-
group, single-center study was designed to evaluate the
clinical efficacy of pricking blood at ExHN 9 for the treat-
ment of NAR relative to the control group, which involved
administration of acupuncture treatment at LI 20.
Design
This study will be a randomized, real acupuncture-con-
trolled, assessor single-blinded and single-center pilot
trial. The study will be conducted in the following
order: enrollment after screening via inclusion and
exclusion criteria, randomization, a treatment period of
3 weeks, and assessment (Figure 1).
Participants and eligibility
Inclusion criteria
Eligible for inclusion in this study will be patients ≥ 8
years of age with a diagnosis of NAR and at least a 3-
month history of continuous nasal symptoms related to
defined triggers (for example, changes in temperature
and/or humidity, strong odors, and airborne irritants).
Patients must have had a history of negative results in
allergic tests (MAST test, serum IgE) and an eosinophil
count within a normal range.
Exclusion criteria
Patients that had a history of nasal surgery, nasal polyp,
psychiatric disorders, drug addiction, and autoimmune
disease will be excluded, as well as patients that could
not be subjected to acupuncture treatment, such as indi-
viduals that were pregnant or had a blood clotting disor-
der. Participants will be ineligible if they have undergone
acupuncture treatment or Western medical treatment
for rhinitis within 1 month of taking cold medicine,
within 2 weeks prior to registration, or if cold medicine
was taken during the trial. Patients who were treated
with gastritis, gastric ulcer (using H2 blocker antiacid),
who had plans to participate in another clinical trial
during this clinical trial, who participated in another
clinical trial within 6 months, or who are not willing to
not comply with the protocol of this study protocol will
also be excluded. Within 3 weeks after enrollment in
this trial, no concomitant therapy will be permitted.
Recruitment
Participants will be recruited via an internet advertise-
ment posted on the website of the Kyung Hee Medical
Center and via ad-posters.
Figure 1 Flow chart of the study.
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After enrollment, participants will be randomly assigned to
control and experimental groups. The allocation ratio will
be 1:1. Randomization will be performed at a site remote
from trial location. Random numbers will be generated
using a computerized random-number generator through
the block-randomization method (Excel, Microsoft Office
2007) for sequence generation. Two separate databases will
be generated: a ‘patient’ database, which lists basic informa-
tion, such as the patient name, contact details, and so on,
and a ‘randomization’ database, which contained data on
patients that have been registered in the trial along with
their allocations. The ‘patients’ database will be accessible
to any researcher whereas the ‘randomization’ database will
be password-protected so that it will be accessible only by
the principal investigator and a nominated statistician [16].
The assessor, who will not be the acupuncture practitioner,
and who will be blinded to the allocation results until the
end of study, will assess the outcome of treatment.
Intervention
Three sessions will be used for both pricking the blood
at ExHN 9 and acupuncture treatment at LI 20. The
sessions will be administered over a period of 3 weeks
(one session per week). Certified acupuncture practi-
tioners who have a minimum of 3 years of clinical
experience obtained after a 6-year oriental medical col-
lege course will perform the acupuncture treatment.
The practitioners will take a one-day training course for
this trial. This course will include the study protocol,
methods for acupuncture treatment, and basic informa-
tion on clinical research.
Pricking blood at ExHN 9
Three sessions of pricking blood at ExHN will be per-
formed once per week for 3 weeks in patients assigned
to the experimental group. Patients that will receive acu-
puncture treatment will be pricked on the intranasal
membrane at bilateral ExHN 9, which is located at the
junction between the mucosa of the alar cartilage of the
nose and the nasal concha in the nostril. This point will
be treated with 0.30 × 120 mm disposable acupuncture
needles (Dongbang Co., Korea) according to ‘WHO
Standard Acupuncture Point Locations’ in the Western
Pacific Region [17].
Acupuncture treatment at LI 20
Three sessions of acupuncture treatment at LI 20 will be
performed once per week for 3 weeks in patients
assigned to the control group. Patients will receive acu-
puncture treatment at bilateral LI 20. For bilateral LI 20,
needles will be inserted obliquely toward their ipsilateral
nostrils to a depth of 0.3 cm. This point will be treated
with 0.30 × 40 mm disposable acupuncture needles
(Dongbang Co., Korea) according to ‘WHO Standard
Acupuncture Point Locations’ in the Western Pacific
Region [17]. Patients will remain in the supine position
for 15 min during acupuncture treatment.
Outcome measures
Primary outcome
Primary outcomes will be presented by mean change in
total nasal symptom score (TNSS) from baseline to the
end of the trial. TNSS is a scoring system that consisted
of rhinorrhea, sneezing, nasal itching, and nasal obstruc-
tion, which are scored on a severity scale from 0 to 3 (0
= none, 1 = mild, 2 = moderate, and 3 = severe). The
TNSS is calculated by summation of all four symptom
scores [5,7]. For each visit at baseline and the end of
trial, the patient will record his nasal symptoms using
the TNSS scoring system.
Secondary outcomes




The MiniRQLQ consists of five domains with a total of
14 questions: two questions for practical problems, and
three questions each for activity limitations, nose, eye,
and other symptoms [18]. The MiniRQLQ is a self-
administered scoring system. The patients will mark one
of the seven Likert-like scales (0 = no impairment to 6
= maximum impairment) for each of the 14 questions.
Statistical methods
Statistical analysis plan
Statistical analysis will be conducted on an intention-to-
treat basis with a 95% confidence interval using SPSS
version 12.0 for Windows. Missing values for patients
that drop out of the study will be analyzed using the
last observation carried forward (LOCF) method. Data
will be displayed as the mean ± standard deviation (SD)
for continuous data or n (%) for categorical data. To
control for baseline differences between groups, vari-
ables that are significantly different at baseline will serve
as covariates in the analyses.
Demographic and clinical characteristics
Demographic and clinical characteristics of participants
in the control and experimental group will be compared
upon admission using an independent sample T-test
(continuous data) and chi-square analysis (categorical
data).
Efficacy analysis
The statistical calculation for the paired sample T-test
or independent sample T-test will be done for the mean
change of TNSS and miniRQLQ score in comparison
between and within groups from baseline to the end of
trial. Non-parametric methods will be used when
assumptions of normality are violated.
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All unexpected adverse events related to pricking blood
at ExHN 9 and acupuncture treatment at LI 20 will be
reported to the investigator or acupuncture practitioner
by participants and written on the individual case report
form by the investigator. Safety will be assessed using
clinical laboratory tests, vital sign measurements, and
adverse events. Clinical laboratory tests, including AST/
ALT, BUN/creatinine, red blood cell (RBC) count, white
blood cell (WBC) count, hemoglobin, hematocrit, mean
cell volume (MCV), mean cell hemoglobin (MCH),
mean cell hemoglobin concentration (MCHC), number
of platelets, and number of differentiated cells will be
determined at weeks 0 (baseline) and 3 (end of the
trial). Vital signs of each participant will be checked by
monitoring adverse events (pain on the acne lesion or
other sites, nausea/vomiting, fatigue, allergic reaction,
and any adverse events related to acupuncture) after
each visit.
Sample size
This study is a pilot study to evaluate the clinical effects
of pricking blood at ExHN 9 on NAR. Because this trial
will be designed for a short duration, lasting 3 weeks,
with the intention of decreasing the drop-out rate, the
desired sample size for this pilot study is 50 patients,
with 25 for each group, assuming a drop-out rate of
20%.
Discussion
A placebo-control group is a decisive tool to evaluate
whether the clinical effectiveness of an intervention is
truly due to the characteristic elements of an interven-
tion [19]. Even though several recent large randomized
trials found clinically relevant effects of acupuncture
over no treatment or routine care, blinded trials com-
paring acupuncture to sham interventions often
reported only minor or no differences [20]. A recent
Cochrane review on placebo interventions for all clinical
conditions showed that placebo interventions have no
important clinical effects in general, but in certain set-
tings, placebo interventions can influence patient-
reported outcomes and physical placebos including
sham acupuncture were associated with larger effects
over no-treatment control groups than pharmacological
placebos [21]. Thus, in trials to evaluate the clinical
effect of acupuncture treatment, a control group must
be included because a sham or placebo control can
affect outcomes in certain designed settings. In particu-
lar, in Korea, several patients have used acupuncture
treatment and are familiar with acupuncture treatment.
Because it is difficult to apply a placebo-control, includ-
ing sham acupuncture, to Korean patients, only minor
or no differences are often reported in blinded trials
that compare acupuncture to sham interventions [20].
In this study, we will use real acupuncture treatment as
the control group. Acupuncture treatment at LI 20 is
the most common therapy used to treat patients with
nasal disease in the clinical practice of Oriental medi-
cine [9-12]. In this study, the effect of pricking blood at
ExHN 9 which is modified acupuncture treatment
method, to reduce the nasal congestion and hypersensi-
tivity will be evaluated [13-15]. Therefore, acupuncture
treatment at LI 20 will be used as the control group to
access the effectiveness of pricking blood at ExHN 9.
The primary goal of treating NAR patients is to give
symptomatic relief. So, the primary outcome that will be
evaluated in this study is the mean change in TNSS from
baseline to the end of the trial. Since NAR is a condition
that markedly affects the quality of life, we will also
examine the mean change in MiniRQLQ scores from
baseline to the end of trial as a secondary outcome.
This study will be the first randomized trial to evaluate
the efficacy of pricking blood at ExHN 9 for the treat-
ment of NAR. The main focus of this study is to investi-
gate the effectiveness of pricking blood at ExHN 9 in
decreasing the TNSS, as a primary outcome, relative to
acupuncture treatment at LI 20, which is commonly used
in clinical practice and has been shown to be effective in
treating patients with chronic rhinitis including NAR.
This trial will provide information needed to answer rele-
vant clinical questions regarding the efficacy of pricking
blood at ExHN 9 for the treatment of NAR. Although the
size of this trial is small and cannot provide conclusive
results on the effectiveness of pricking blood at ExHN 9,
if positive results are obtained, a large clinical trial will be




The study protocol and the written informed consent
were approved by the institutional review board (IRB) of
the Oriental Medical Hospital at Kyung Hee Medical
Center (KOMC MIRB 2010-04). Each participant will be
notified regarding the study protocol. Written informed
consent will be obtained from each patient.
Abbreviations
ALT: Alanine transaminase; AST: Aspartate transaminase; BUN: Blood urea
nitrogen; ExHN 9: Neiyingxiang; HRV: Heart rate variation; IRB: Institutional
review board; LI 20: Waiyingxiang; LOCF: Last observation carried forward;
MAST: Multiple antigen simultaneous test; MCH: Mean cell hemoglobin;
MCHC: Mean cell hemoglobin concentration; MCV: Mean cell volume;
MiniRQLQ: Mini-rhinoconjunctivitis quality-of-life questionnaire; NAR: Non-
allergic rhinopathy; RBC: Red blood cell; RCT: Randomized controlled trial;
SD: Standard; WBC: White blood cell.
Acknowledgements
None.
Kim et al. Trials 2012, 13:37
http://www.trialsjournal.com/content/13/1/37
Page 4 of 5Author details
1Department of Ophthalmology & Otolaryngology & Dermatology, College
of Oriental Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu,
Seoul 130-701, Republic of Korea.
2Copyeonhan Korean medical clinic, #201,
Samsung-chereville, 319-12, Sinjung-dong, Yangcheon-ru, Seoul 158-764,
Republic of Korea.
Authors’ contributions
KSK participated in the study design, including statistical design, and drafted
the manuscript. SGG participated in the study design and critical revision of
the manuscripts. YBK was the general supervisor for this research and
participated in both the study design and critical revision of the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 January 2012 Accepted: 16 April 2012
Published: 16 April 2012
References
1. Kaliner MA: Nonallergic rhinopathy (formerly known as vasomotor
rhinitis). Immunol Allergy Clin North Am 2011, 31:441-455.
2. Lieberman P, Meltzer EO, LaForce CF, Darter AL, Tort MJ: Two-week
comparison study of olopatadine hydrochloride nasal spray 0.6% versus
azelastine hydrochloride nasal spray 0.1% in patients with vasomotor
rhinitis. Allergy Asthma Proc 2011, 32:151-158.
3. Tran NP, Vickery J, Blaiss MS: Management of rhinitis: allergic and non-
allergic. Allergy Asthma Immunol Res 2011, 3:148-156.
4. Smith PK, Collins J: Olopatadine 0.6% nasal spray protects from
vasomotor challenge in patients with severe vasomotor rhinitis. Am J
Rhinol Allergy 2011, 25:e149-e152.
5. Maiti R, Jaida J, Rahman J, Gaddam R, Palani A: Olopatadine hydrochloride
and rupatadine fumarate in seasonal allergic rhinitis: A comparative
study of efficacy and safety. J Pharmacol Pharmacother 2011, 2:270-276.
6. Lee MS, Pittler MH, Shin BC, Kim JI, Ernst E: Acupuncture for allergic
rhinitis: a systematic review. Ann Allergy Asthma Immunol 2009,
102:269-279.
7. Kim AR, Choi JY, Kim JI, Jung SY, Choi SM: Acupuncture treatment of a
patient with persistent allergic rhinitis complicated by rhinosinusitis and
asthma. Evid Based Complement Alternat Med 2011, 2011:798081.
8. Fleckenstein J, Raab C, Gleditsch J, Ostertag P, Rasp G, Stör W, Irnich D:
Impact of acupuncture on vasomotor rhinitis: a randomized placebo-
controlled pilot study. J Altern Complement Med 2009, 15:391-398.
9. Zhen M, He F, Wu M, Zhen L: Effects of acupuncture at different groups
of Yangming Meridian points on allergic rhinitis. Shanghai J Acu-Mox
2011, 30:35-37.
10. Zhang C, Liu Z: Analysis of acupoints for treating nasal conditions in
acupuncture verses. J Acupunct Tuina Sci 2009, 7:185-187.
11. Chen Z: Clinical observation on acupuncture for treatment of allergic
rhinitis. Chin Acupunct Moxibusion 2007, 27:578-580.
12. He T, Li H, Zhao Y, Gao H: Treatment of 60 cases of allergic rhinitis
mainly with point-through-point method. Chin Acupunct Moxibusion 2006,
26:110-112.
13. Liu Q, Liu J: Acupuncture treatment at Neiyingxiang on olfactory
disorder. Beijing Acta Chi Med Pharmacol 2011, 1:21-22.
14. Hu Y, Liu J: Acupuncture treatment at Neiyingxiang on chronic rhinitis. J
Chin Med 1995, 36:476-477.
15. Sun L, You Y: Pricking blood at Neiyingeixang in 42 patients with sequel
of Bell’s palsy. J Sichuan Tradition Chin Med 2004, 22:93-94.
16. Vickers AJ: How to randomize. J Soc Integr Oncol 2006, 4:194-198.
17. WHO Regional Office for the Western Pacific: WHO standard Acupuncture
Point Locations in the Western Pacific Region Manila: World Health
Organization; 2008.
18. Junifer EF, Thompson AK, Ferrie PJ, Roberts JN: Development and
validation of the mini rhinoconjunctivitis quality of life questionnaire.
Clin Exp Allergy 2000, 30:132-140.
19. Linde K, Niemann K, Meissner K: Are sham acupuncture interventions
more effective than (other) placebos? A re-analysis of data from the
Cochrane review on placebo effects. Forsch Komplementmed 2010,
17:259-264.
20. Linde K, Niemann K, Schneider A, Meissner K: How large are the
nonspecific effects of acupuncture? A meta-analysis of randomized
controlled trials. BMC Med 2010, 23:75.
21. Hróbjartsson A, Gøtzsche PC: Placebo interventions for all clinical
conditions. Cochrane Database Syst Rev 2010, 20:CD003974.
doi:10.1186/1745-6215-13-37
Cite this article as: Kim et al.: Clinical effect of pricking blood at
neiyingxiang (ExHN 9) on non-allergic rhinopathy: study protocol for a
randomized controlled trial. Trials 2012 13:37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kim et al. Trials 2012, 13:37
http://www.trialsjournal.com/content/13/1/37
Page 5 of 5